ATTO Director Colin Walsh Buys $8.5M in Cluster Buy

SEC Form 4 filing showing Colin Walsh's insider stock purchase at Attovia Therapeutics

A new Form 4 filing shows Colin Walsh, a director at Attovia Therapeutics, Inc. (ATTO), purchased 500,000 shares of company stock on the open market on August 6, 2026. The purchase price was $17.00 per share, bringing the total outlay to $8,500,000.00. Following the transaction, Walsh’s indirect holdings — held via a trust or entity … Read more

ATTO: Goldman Sachs Buys $8.5M, Part of Cluster Buy

Illustration of SEC Form 4 insider trading disclosure for Attovia Therapeutics stock purchase

Goldman Sachs Group Inc. disclosed the purchase of 500,000 shares of Attovia Therapeutics, Inc. (ATTO) on the open market on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece for a total outlay of $8,500,000. Following the transaction, Goldman Sachs holds 3,020,632 shares indirectly, through … Read more

ATTO: venBio Buys $6.5M in Attovia Therapeutics Stock

SEC Form 4 insider trading disclosure showing venBio Global Strategic Fund IV's purchase of Attovia Therapeutics shares

Attovia Therapeutics, Inc. (ATTO) has another notable name on its insider buying ledger. venBio Global Strategic Fund IV, L.P., listed as an insider of the company, purchased 382,352 shares on the open market on August 6, 2026, at a price of $17.00 per share. The transaction totaled $6,499,984.00, funded directly by the fund rather than … Read more

ATTO: Sanofi Buys $5.1M in Attovia Therapeutics Shares

SEC Form 4 filing showing Sanofi's insider stock purchase in Attovia Therapeutics (ATTO)

Sanofi has disclosed a substantial open-market purchase of shares in Attovia Therapeutics, Inc. (ATTO), according to a Form 4 filed with the SEC. The filing shows Sanofi bought 300,000 shares on August 6, 2026 at a price of $17.00 per share, a transaction valued at $5,100,000.00. Following the purchase, Sanofi’s stake in Attovia stands at … Read more

ATTO: Redmile Group Buys $3.4M in Attovia Amid Cluster Buying

Chart showing insider stock purchase activity at Attovia Therapeutics (ATTO) in August 2026

Attovia Therapeutics, Inc. (NASDAQ: ATTO) is showing a fresh cluster of insider buying, with Redmile Group, LLC — a 10%+ owner of the company — disclosing an open-market purchase of 200,000 shares at $17.00 per share on August 6, 2026. The transaction, filed on Form 4, totaled $3,400,000 and brings Redmile Group’s directly held stake … Read more

Frazier Life Sciences Buys $10M of Attovia Therapeutics (ATTO)

SEC Form 4 filing document showing an insider stock purchase at Attovia Therapeutics

Frazier Life Sciences XI, L.P., an insider at Attovia Therapeutics, Inc. (ATTO), disclosed an open-market purchase of 588,235 shares on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece, for a total outlay of $9,999,995.00 — a purchase sized almost exactly to the $10 million … Read more